Ridgeback Biotherapeutics LP — Federal Contractor Profile
RIDGEBACK BIOTHERAPEUTICS LP Secures $39.5M in Federal Contracts
Contractor Overview
Total Contract Value: $39,534,669 ($39.5M)
Total Awards: 2
Company Profile
RIDGEBACK BIOTHERAPEUTICS LP is a federal contractor with a total government contract value of $39.5 million, spanning two contracts with an average size of $1,976,733.50. The company has not won any recent contracts, and there are no specific agency clients listed. This contractor's primary focus appears to be in biotechnology and therapeutics, given the nature of their contracts. The company's business model is heavily reliant on a few large contracts, indicating a high level of dependency on government funding. The lack of competitive bidding suggests that the company may be leveraging its expertise in niche areas to secure sole-source contracts. However, the absence of recent contracts and the lack of detailed information on specific projects and performance history makes it challenging to assess the company's current trajectory and market position. Given the high value of their contracts and the specialized nature of their work, it is crucial to monitor their performance and ensure that they provide good value for taxpayer money.
Specializations
- Biotechnology
- Therapeutics
- Pharmaceutical Research
- Clinical Trials
- Regenerative Medicine
- Biological Products
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients listed)
Growth Trajectory: Stable (based on two contracts with no recent activity)
Sole Source Rate: 100%
Recompete Rate: 0% (no recompete/renewal contracts)
Competitive Position
RIDGEBACK BIOTHERAPEUTICS LP operates in a niche market, leveraging its expertise in biotechnology and therapeutics to secure sole-source contracts. While the company has not demonstrated a competitive edge in recent years, its focus on specialized areas suggests it may be a dominant player in those niches. However, the lack of recent contracts and the absence of detailed performance history make it difficult to assess its current market position and competitive advantages.
Value to Taxpayers
RIDGEBACK BIOTHERAPEUTICS LP's contracts are of significant value, with an average of $1,976,733.50 per contract. Given the specialized nature of their work, the company may provide unique and essential services to the government. However, the absence of recent contracts and the lack of detailed performance history make it challenging to assess whether the company provides good value for taxpayer money. The high value of their contracts and the specialized nature of their work suggest that the company should be closely monitored to ensure that it delivers on its promises and provides value for the money spent.
Agency Relationships
RIDGEBACK BIOTHERAPEUTICS LP has not been listed as a client for any specific government agencies, making it difficult to assess the nature and extent of their relationship with the government. The lack of detailed information on agency clients and the absence of recent contracts raise concerns about the company's current dependency on government funding. Without a clear understanding of their client base, it is challenging to assess the risks associated with relying on this contractor.
Red Flags
- No recent contracts: The absence of recent contracts suggests that the company may be facing challenges in securing new business, which could indicate financial or operational issues.
- Sole-source contracts: The company has won all contracts through sole-source procurement, which may limit competition and potentially lead to higher costs for the government.
- Lack of detailed performance history: The absence of specific project details and performance metrics makes it difficult to assess the company's track record and reliability.
Green Flags
- High contract value: The company's contracts are of significant value, indicating that they are working on important and specialized projects.
- Specialized expertise: The company's focus on biotechnology and therapeutics suggests that they have unique and essential skills that are in high demand.
- Potential for niche dominance: Given the specialized nature of their work, the company may be a dominant player in niche areas, providing critical services to the government.
Key Contracts
RIDGEBACK BIOTHERAPEUTICS LP has secured two contracts with a total value of $39.5 million. While the company has not provided specific details on the nature of these contracts, the high value and the sole-source nature of the contracts suggest that they are working on important and specialized projects. The lack of recent contracts and the absence of detailed performance history make it challenging to assess the company's capabilities and performance. However, the high value of their contracts and the specialized nature of their work suggest that the company should be closely monitored to ensure that it delivers on its promises and provides value for the money spent.
Frequently Asked Questions
What does RIDGEBACK BIOTHERAPEUTICS LP do for the federal government?
RIDGEBACK BIOTHERAPEUTICS LP specializes in biotechnology and therapeutics, providing essential services such as pharmaceutical research, clinical trials, and the development of biological products. The company's work is critical for advancing medical treatments and therapies, supporting the government's mission in healthcare and public health.
How much taxpayer money does RIDGEBACK BIOTHERAPEUTICS LP receive?
RIDGEBACK BIOTHERAPEUTICS LP has secured a total of $39.5 million in federal contracts, with an average contract size of $1,976,733.50. The company has not won any recent contracts, and there are no specific details on the nature of these contracts, making it challenging to provide a detailed financial breakdown.
Is RIDGEBACK BIOTHERAPEUTICS LP good value for taxpayer money?
RIDGEBACK BIOTHERAPEUTICS LP's contracts are of significant value, with an average of $1,976,733.50 per contract. Given the specialized nature of their work, the company may provide unique and essential services to the government. However, the absence of recent contracts and the lack of detailed performance history make it challenging to assess whether the company provides good value for taxpayer money. The high value of their contracts and the specialized nature of their work suggest that the company should be closely monitored to ensure that it delivers on its promises and provides value for the money spent.
How does RIDGEBACK BIOTHERAPEUTICS LP win its contracts?
RIDGEBACK BIOTHERAPEUTICS LP has won all of its contracts through sole-source procurement, indicating that the company leverages its specialized expertise and niche market position to secure contracts without competition. The lack of recent contracts and the absence of detailed performance history make it challenging to assess the company's competitive edge and the factors that contribute to its success in winning contracts.
What agencies use RIDGEBACK BIOTHERAPEUTICS LP most?
RIDGEBACK BIOTHERAPEUTICS LP has not been listed as a client for any specific government agencies, making it difficult to assess the nature and extent of their relationship with the government. The lack of detailed information on agency clients and the absence of recent contracts raise concerns about the company's current dependency on government funding. Without a clear understanding of their client base, it is challenging to assess the risks associated with relying on this contractor.
What are the risks of relying on RIDGEBACK BIOTHERAPEUTICS LP?
The risks of relying on RIDGEBACK BIOTHERAPEUTICS LP include the absence of recent contracts, which may indicate financial or operational challenges. The company's reliance on sole-source contracts and the lack of detailed performance history make it difficult to assess the reliability and performance of the company. Additionally, the high value of their contracts and the specialized nature of their work suggest that any issues with the company could have significant financial implications for the government.
How does RIDGEBACK BIOTHERAPEUTICS LP compare to similar contractors?
RIDGEBACK BIOTHERAPEUTICS LP operates in a niche market, leveraging its expertise in biotechnology and therapeutics to secure sole-source contracts. While the company has not demonstrated a competitive edge in recent years, its focus on specialized areas suggests it may be a dominant player in those niches. However, the lack of recent contracts and the absence of detailed performance history make it difficult to assess its current market position and competitive advantages. In comparison to industry peers, the company's high contract value and specialized expertise suggest that it may be a key player in its niche, but the absence of recent activity and detailed performance metrics make it challenging to make a comprehensive comparison.
Recent Federal Contracts
Ridgeback Biotherapeutics LP has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS Awards $19.8M to Ridgeback Biotherapeutics for Ebola Treatment R&D | Department of Health and Human Services | $19.8M | N/A |